Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience
| Autor: | S. Kalla, D. Hauteville, J. M. Extra, M. Itzhaki, Michel Marty, Sandrine Faivre, Esteban Cvitkovic, L. M. Dourte, O. Bourdon, M. A. Bensmaine |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Organoplatinum Compounds Paclitaxel medicine.medical_treatment Neutropenia Gastroenterology chemistry.chemical_compound Internal medicine Ovarian carcinoma Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Retrospective Studies Ovarian Neoplasms Salvage Therapy Chemotherapy business.industry Hematology medicine.disease Carboplatin Oxaliplatin Surgery Oncology chemistry Drug Resistance Neoplasm Female Ovarian cancer business Febrile neutropenia medicine.drug |
| Zdroj: | Annals of Oncology. 10:1125-1128 |
| ISSN: | 0923-7534 |
| DOI: | 10.1023/a:1008334215414 |
| Popis: | Summary Purpose Compassionate-use oxaliplatin-paclitaxel was assessed for toxicity and efficacy according to clinical platinum resistance status in cisplatin-carboplatin-pretreated advanced ovarian cancer patients. Patients and methods Thirty-seven patients, retrospectively grouped into four oxaliplatin-paclitaxel dose levels (mg/m2): (DL1: 100/135; DL2: 130–135/135; DL3: 100/160–175; DL4: 130–135/160–175), received oxaliplatin and paclitaxel every three to four weeks. Results Thirty-one of thirty-seven treated patients were evaluable for activity, with 1 complete and 14 partial responses, (objective response rate: 48%, 95% CI: 31–66). Of 18 platinum-resistant patients 6 responded, and of 13 platinum-sensitive patients, 9 responded. One patient (3%) had two febrile neutropenia episodes, and eight (22%) and eleven patients (30%) had grades 3 and 4 neutropenia, respectively. Six patients (16%) experienced grade 3 peripheral neuropathy. The median response duration was 10.8 months, with a 23-month (range 8–54) median follow-up. Median progression-free and overall survivals were 9 months (95% CI: 7–12), and 25.2 months (95% CI: 12–39), respectively. Conclusions The antitumour activity of oxaliplatin-paclitaxel in platinum-resistant ovarian cancer patients accords with experimental data on the agents' lack of cross-resistance. Time-related progression parameters confirm it as a promising salvage treatment option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|